Karyopharm (KPTI) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$146.6M

Revenue (quarter)

$33.4M

Revenue growth (year over year)

−11.86%

Gross profit (trailing twelve months)

$140.6M

Gross margin

95.89%

Net income (trailing twelve months)

−$224.7M

Net income (quarter)

−$67.0M

Net income growth (year over year)

−79.92%

Net margin

−153.28%

Return on equity

—

EPS (trailing twelve months)

−$14.33

Book value per share

−$14.56

P/E (trailing twelve months)

—

Price to book

—

Debt to assets

396.60%

Payout ratio

—

Dividend yield

—

Company profile

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).

• Is Karyopharm (KPTI) profitable?

  No. Karyopharm reported a net loss of $224.7M over the trailing twelve months.

• How much revenue does Karyopharm (KPTI) make?

  Karyopharm generated $146.6M in revenue over the trailing twelve months, down 11.86% year over year.

• How do I buy stock in Karyopharm (KPTI)?

  KPTI trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.